Description

ZYVOLID TABLET is a broad-spectrum oxazolidinone antibiotic that contains Linezolid, designed to combat serious bacterial infections, especially those caused by Gram-positive organisms resistant to multiple antibiotics, including MRSA (Methicillin-Resistant Staphylococcus aureus) and VRE (Vancomycin-Resistant Enterococci).

Linezolid inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit, preventing the formation of the initiation complex necessary for bacterial translation. Due to its unique mechanism of action, ZYVOLID remains effective where other antibiotics fail, making it a preferred choice in hospital and ICU settings for resistant infections.

Manufactured under stringent WHO-GMP and ISO certified conditions, ZYVOLID TABLET is represented by BLUEPILL EXPRESS, a globally renowned pharmaceutical exporter committed to delivering quality-assured medicines worldwide. The product is available for bulk purchase and third-party labeling, ensuring regulatory compliance across international markets in Africa, Latin America, CIS, Southeast Asia, and the Middle East.

• Oxazolidinone Antibiotic

• Anti-MRSA/Anti-VRE Agent

ZYVOLID (Linezolid) acts by selectively inhibiting bacterial protein synthesis. It binds to the 23S portion of the 50S ribosomal subunit, preventing the formation of the initiation complex and halting bacterial growth. It is bacteriostatic against most organisms and bactericidal against some strains like Streptococcus pneumoniae.

• Methicillin-resistant Staphylococcus aureus (MRSA) infections

• Vancomycin-resistant Enterococci (VRE) infections

• Nosocomial pneumonia

• Community-acquired pneumonia

• Complicated and uncomplicated skin and soft tissue infections

• Diabetic foot infections (without osteomyelitis)

• Effective against multidrug-resistant Gram-positive infections

• Oral administration offers an alternative to IV therapy

• Excellent tissue and lung penetration

• Can be used in both community and hospital-acquired infections

• Available globally via BLUEPILL EXPRESS, ensuring export compliance

• Suitable for private labeling and customized packaging

• Typical adult dosage: 600 mg every 12 hours for 10–14 days, or as directed by a physician

• May be taken with or without food

• Renal and hepatic function should be monitored during prolonged use

• Avoid concurrent use of serotonergic agents due to risk of serotonin syndrome

• Prolonged use may result in bone marrow suppression; monitor CBC regularly

• Risk of serotonin syndrome when used with SSRIs or MAOIs

• Not recommended for use during pregnancy or lactation unless clearly necessary

• May cause lactic acidosis, optic neuropathy, or peripheral neuropathy with long-term use

• Use cautiously in patients with a history of seizures

• Nausea, vomiting, or diarrhea

• Headache or dizziness

• Anemia or thrombocytopenia

• Neuropathy (with long-term use)

• Rash or skin reactions

BLUEPILL EXPRESS ensures that ZYVOLID TABLET is produced in certified facilities following international manufacturing protocols, offering assurance of quality, safety, and efficacy. We are a preferred partner for pharmaceutical procurement across developing and regulated markets thanks to our reliable logistics, complete documentation, and client-focused solutions like custom labeling, third-party manufacturing, and bulk export packaging.

Our dedication to quality and global compliance makes us the exporter of choice for hospitals, tenders, and private medical institutions seeking effective antimicrobials like ZYVOLID.